The DNA sequence specificity of an ellipticine derivative bearing an aminoalkyl side chain has been determined by a variety of footprintlng methods. The drug exhibits sequence selective binding and discriminates against runs of adenines or thymines. Binding is shown to occur at various sequences with a preference for GC rich regions of DNA. A large enhancement of DNAase I and of hydroxyl radical cleavage in regions rich in A's or T's is observed together with hyperreactlvlty of adenines towards dlethylpyrocarbonate in the presence of drug. This indicates the occurrence of drug-induced changes in critical conformational features of DNA. The total absence of hyperreactivity of guanine residues towards diethylpyrocarbonate appears to be related to the sequence selectivity of drug binding. No alteration of the dimethyl sulphate and methylene blue-induced cleavage of DNA Is observed. Irradiation of ellipticine derivative-DNA complexes with UV light followed by alkali treatment leads to selective photocleavage at guanine residues, consistent with the deduced degree of selectivity of the binding reaction
INTRODUCTION
Ellipticine and its analogues are highly cytotoxic towards various experimental tumor cells. Of the numerous derivatives to have been synthesized, Celiptium, (N-methyl-9-hydroxy-ellipticiniurn, NMHE), elicits therapeutic activity against bone metastasis of breast cancer [1, 2] .
The biological action of these drugs is believed to result directly from their binding to DNA in vivo. The binding, measured in vitro, is tight (Ka=10 5 -10 7 ) [3, 4] , causing inhibition of DNA polymerases and DNA-dependent RNA polymerases [5] . But while DNA may be involved in the biological activity of these drugs, a direct correlation between their toxicity and their ability to intercalate between DNA base pairs does not exist [3, 6] ; therefore some other factors must be required.
It has been demonstrated that ellipticines can induce proteinassociated DNA strand breaks [7, 8] , due to the trapping of topoisomerase n by stabilisation of a reversible enzyme-DNA cleavable complex [9] . Recent studies strongly suggest that the trapping of this complex could be responsible for the cytotoxic action of the drug. The DNA breaks by topoisomerase II do not occur at random. DNA topoisomerase H itself induces a low level of breaks which occur preferentially at particular sequences [10] . Ellipticine analogues, like other intercalating drugs, increase the probability of hidden breaks at these sequences (which correspond to DNAase I hypersensitive sites [11] ) but also promote breakages at other positions, which are different from those seen with the topoisomerase H-binding drugs amsacrine and VP16 [12] . Clearly, the drug itself influences the location of the breakage points. Therefore it is of the utmost importance to obtain a good understanding of the exact sites of action of such compounds which intercalate into DNA, if we are to discern how to modify them so as to increase their lethal action on cancer cells.
In this study, we report investigations that probe the sequence selectivity of an ellipticine derivative bearing a -NH-(CH2)3-NH2 substituent at position 1 and -OCH 3 at position 9 ( Figure 1 ). This ellipticine derivative is a functionalised analogue which can be linked to other molecules by its free amine group. It has been covalently linked by this NH 2 group to (i) an oligonucleotide for the study of double-strand DNA sequence recognition via triple helix formation associated with an artificial photoendonuclease activity [13] , and (ii) a distamycin moiety to form a hybrid drug able to bind to DNA by both intercalation and minor groove interactions [14] . Because it provides the basic building block for the design of such drugs, it is important to determine accurately the nature and selectivity of DNA binding by this ellipticine derivative itself.
Experiments with synthetic DNAs have shown a slight discrimination of ellipticine against the GC polymer [15] . However, these results do not permit an unambiguous determination of the nature and location of preferred binding sites in a natural DNA of mixed nucleotide sequence. A variety of sequencing assays exist to probe the selectivity of binding. We have chosen to use a wide range of enzymic (DNAase I, micrococcal nuclease) and chemical (iron-EDTA, diethylpyrocarbonate, dimethyl sulphate and methylene blue) DNA-cleavage techniques to examine the specificity and the structural consequences of binding by the ellipticine derivative to several DNA fragments. We also report the DNA cleaving ability of this ellipticine derivative under photoexcitation. In addition, by examining how well the results correlate between techniques which provide complementary information on binding (as well as those which duplicate each other) we can make some assessment of the techniques themselves.
MATERIALS AND METHODS Enzyme
Deoxyribonuclease I (DNAase I) was purchased from Sigma Chemical Co. (St. Louis, MO) and was stored at -20°C at a concentration of 7200 units/ml in 150mM NaCl/lmM MgCl 2 . This stock solution was diluted to working concentrations immediately before use. Drug 1-substitution was effected by reaction of 1-chloro, 5,11-dimethyl, 9-methoxy ellipticine [16] with diaminopropane as previously described [3, 17] . A stock solution (lmM) of the compound was prepared in methanol since it is very insoluble in water. This solution was stored at -20°C in the dark and diluted to working concentrations in lOmM Tris-HCl buffer pH 7.0 containing lOmM NaCl. The final methanol concentration did not exceed 1-2% (v:v). Such a low concentration of methanol is known not to affect cleavage of a restriction fragment by DNAase I [18] .
DNA substrate
Plasmid pKMA-98 was amplified in E. coli by culture and isolated according to published methods [19] . The 160 base-pair tyr T DNA fragment was isolated from the plasmid and labelled according to previously described procedures [18] [19] [20] [21] [22] . Incubation with the Klenow fragment of DNA polymerase I (Boehringer) and [a-
32 P]dCTP leads to selective labelling of the 3'-end of the top strand (Watson strand) whereas incubation with [a-32 P]dATP leads to selective labelling of the 3'-end of the bottom strand (Crick strand).
The plasmid pBS (Stratagene, La Jolla, CA.) was digested to completion with Pvu II followed by either Ava I or Eco RI restriction enzymes, giving fragments (the 117 base pair Pvu n/Eco RI and 253 base pair Pvu WAval) suitable for 3' end labelling. Enzyme heat-denaturation and two ethanol precipitations were effected before the 3'-end labelling with [a-32 P]dCTP (60mCi) and the Klenow fragment of DNA polymerase I (20 units) under standard conditions. Following electrophoresis on polyacrylamide gels, the 117-bp and the 253-bp bands were identified by autoradiography, excised, and isolated by elution in 500mM ammonium acetate, lOmM magnesium acetate buffer.
DNAase I footprinting, electrophoresis, autoradiography and quantification
The procedure for footprinting experiments was exactly as previously described [18] [19] [20] [21] [22] . The cleavage products of the nuclease reactions were analyzed on 0.3 mm thick, 8% polyacrylamide gels containing 8M urea and Tris-Borate-EDTA buffer (pH 8.3). After 2h electrophoresis at 1400V, the gels were fixed in 10% acetic acid, transferred to Whatman 3MM paper, dried under vacuum at 80°C and subjected to autoradiography (Kodak, X-OMAT AR) at -70°C with an intensifying screen. Autoradiographs were scanned using a multi-channel computeroperated gel scanner in the Medical Research Council Laboratory of Molecular Biology (Cambridge). Gel profiles were plotted and displayed on a raster graphics AED screen. The area under each peak was integrated by simple addition of the pixels under the 
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Ell. The tracks labelled 'G' represent dimethyl sulphate-piperidine markers specific for guanine. Numbers at each side of the gels refer to the sequence shown in Figure 3 . Time in minutes after addition of the enzyme is shown at the top of each gel lane.
curve as described by Drew & Travers [19] . In comparing different digestion patterns, care was taken to ensure that the extent of digestion was similar and limited to 20-40% of the starting material so as to minimize the incidence of multiple cuts in any one strand. Data are presented in the form In (Q -In (Q representing the differential cleavage at each bond relative to that in the control (f a is the fractional cleavage at any bond in the presence of the drug and f c is the fractional cleavage of the same bond in the control). The results are displayed on a logarithmic scale for convenience so that positive values indicate enhanced cleavage whereas negative values indicate blockage.
Diethylpyrocarbonate footprinting
The reaction with diethyl pyrocarbonate (DEPC) was performed essentially according to a published protocol [23] . 1/tl of 32 Plabelled DNA was incubated with 19/il of the drug solution (maximal methanol final concentration 5%) for 15 minutes at 37°C. The mixture was kept at 0°C for 3 minutes before addition of DEPC (Sigma). Samples were incubated at room temperature for a further 15 minutes with agitation. The reaction was terminated by addition of sodium acetate to 0.3 M followed by ethanol precipitation and a 70% ethanol wash. The pellet was resuspended in 30/tl of 1 M piperidine, heated at 90°C for 15 minutes, lyophilized and resuspended in 4^1 of dye solution. Electrophoresis, autoradiography and densitometry were carried out as described for DNAase I footprinting.
Hydroxyl radical footprinting, methylation by dimethyl sulphate and reaction with methylene blue
Reactions were carried as previously described [24] [25] [26] .
Photocleavage
Drug was added to solutions containing the 32 P-labelled DNA fragment in lOmM NaCl, lOmM Tris-HCl buffer, pH7.0. The reaction samples (20/*l) were placed on ice and irradiated at a distance of 15cm from a UV lamp (UVP, model UVM-57) with an emission maximum of 302 nm. Then 1/xg of carrier calf thymus DNA was added to each tube, the DNA precipitated with ethanol, resuspended in 30/d of 1M piperidine and heated at 90°C for 15 minutes. Following lyophilisation, the material was dissolved in 5/tl of formamide loading buffer. The DNA was denaturated by heating at 90°C for 4 minutes before transferring to the gel. DNA samples were electrophoresed, in parallel with standard G-sequencing fragments. It should be pointed out that exposure to the 302nm light for 30 minutes resulted in slight cleavage of the DNA control, even in the absence of drug.
RESULTS

Enzymic and hydroxyl radical footprinting
DNAase I digestion patterns observed in the absence and presence of the functional ized ellipticine with both strands of the tyr T fragment are illustrated in Figure 2 . The presence of 10/tM drug clearly alters the digestion pattern compared to that seen in the control lanes with DNA alone. Experiments conducted with lower ellipticine concentrations (1-5/iM) gave a similar pattern of DNAase I cutting. Higher drug concentrations (15-20jtM) required increased enzyme concentration and longer digestion to produce a similar extent of cleavage, although the drug-induced cutting pattern remained essentially the same. Concentrations greater than 20/iM gave no reliable information due to nearcomplete inhibition of the enzyme.
At the concentrations of ellipticine tested, different concentrations of DNAase I are required to ensure a constant extent of cleavage. Thus, at 10/tM drug (Figure 2 ), 20 fold more enzyme (0.72 against 0.036 units/ml) was used to give comparable cutting in drug and control samples. At 1/xM ellipticine only 4-fold excess was necessary. However, no dependence of drug-induced protection patterns on enzyme concentrations was observed.
To gain a more accurate impression of the drug specificity, intensities from selected gel lanes in Figure 2 were measured by densitometry and converted to numerical probabilities of cleavage. A typical result is shown in Figure 3 where the intensities from DNAase I lanes have been converted to probabilities and superimposed on the known sequence. This differential cleavage plot indicates the degree of cleavage at each internucleotide bond relative to that seen in the control.
The most obvious protected zones on the Crick (lower) strand occur at position 21 -25, 69-79, 93-103 and 110-118 which correspond to GC, GG, or CC rich sequences. The size of the protected regions varies from 2 to 8 base pairs, and the larger sites (around position 72 for example) could well represent overlapping binding sites. On this same strand, important areas of enhanced cleavage are visible around positions 30, 50 and 65, none of which are cut particularly well in the control. These regions correspond to runs of A and/or T. On the labelled Watson (upper) strand similar protected and enhanced zones can be identified. There is apparently excellent agreement between sites affected on the two strands.
More interesting are the instances where AT nucleotides are located between two closely spaced strong GC binding sites, as at position 102 -103. Densitometer tracings for this region reveal how poorly the central 5'-TT-3' region sandwiched between G and C nucleotides is protected by binding of the ellipticine. However, GT or TG dinucleotides are often protected, as for example at position 21 -22, 33-34, 37-41, 54-57, and 68-70 on the Crick strand. It also appears that alternating AT sites (3'-TATA-5' sequence at position 87-90 and 3'-TATT-5' sequence at position 109-112) can occasionally be protected.
To extend these observations, similar DNAase I footprinting experiments were performed using the 117bp and 253bp fragments of pBS (see Materials and Methods). As with the tyr T fragment, higher concentrations of DNAase I are required for the drug-treated samples than for the DNA alone. Differential cleavage plots for both DNA fragments are shown in Figure 4 . With these pBS fragments, blockages are relatively weak compared with the clearer protection produced with the tyr T fragment. The pBS fragments contain several GpC and CpG dinucleotide steps to which the drug fails to bind. They do not offer long runs of GC sites such as occur in position 72 -79 and 92 -101 on the tyr T DNA where the stronger binding sites have been found. With the short fragment (117-mer), only 5 sites of small sizes are protected from cleavage, corresponding to the sequences CTG, CCG, GG, GGA and TCG. A pronounced enhancement is apparent in the run of A and T nucleotides around positions 44 and 65 (Figure 4a) .
Neither does the 253-mer exhibit any large binding sites for die ellipticine: only sites of small size can be observed. With this DNA, markedly enhanced cleavage can be seen around positions 38, 60 and 108, (i.e. still in AT-rich sequences, Fig.  4b ). Some interesting subtleties in the interaction can be noted. For example, the trinucleotide GGG at position 67-69 on the 117-mer corresponds to a site of enhanced cutting while the same sequence at position 95 -97 on the Crick strand of the tyr T DNA or 44-46 on the 253-mer forms a protected site. Surprising too is the apparent lack of enhanced cleavage in the sequence ATTA or of any marked inhibition at the sequence CCC and GCGG at positions 85-88, 60-62 and 89-92 respectively of the 117bp DNA fragment (Fig. 4a) . It thus appears that while an overall preference for binding of the drug to GC rich sites exists, the binding to small GC sites is strongly affected by the sequence in neighbouring regions. However, enhanced enzyme cleavage at regions located in runs of A and T nucleotides appears as the major common characteristic of the footprinting patterns with the three DNAs in the presence of the drug.
We have also performed experiments using micrococcal nuclease as a footprinting agent. We observed no great changes in the sensitivity of the tyr T DNA to cleavage by this enzyme in the presence of the ellipticine (data not shown). This enzyme, which cuts exclusively at pA and pT bonds, was too strongly inhibited by ellipticine to use as a footprinting probe.
Experiments employing Fe-EDTA as cleaving agent [24] have been carried out. The presence of 10/iM ellipticine alters the reactivity of the tyr T DNA towards hydroxyl radical treatment. In the absence of drug, (lower trace, fig. 5 ) peaks in cleavage occur around positions 71, 59 and 40 of the tyr T fragment. The addition of drug changes the reactivity such that the extent of cleavage is enhanced at runs of thymines (around position 50) and runs of adenines (around position 30). This confirms results obtained with DNAase I. The internucleotide bonds in the GCrich sequences (from nucleotide positions 72 to 79) are less accessible to hydroxyl radicals than at A and T sequences but are still cleaved, while a clear footprint is observed in this DNA region with DNAase I (Fig. 2, Watson strand) . However no simple protection pattern can be discerned and the nucleotide sequences in protected regions are relatively mixed. This indicates that the ellipticine derivative may bind to many types of structures.
Adenine hyperreactive to DEPC in the presence of ellipticine Diethylpyrocarbonate (DEPC) is a cleavage reagent known to be sensitive to DNA structure [27] . Patterns of DEPC-mediated DNA cleavage of the tyr T Watson strand in the presence of varying concentrations of the ellipticine derivative are presented in Figure 6 . Few cleavage products are visible in the control lanes since this reagent reacts only weakly with double stranded DNA. Moreover the background bands in the control lanes might also arise from the piperidine cleavage reaction alone, which can give a faint purine ladder without any prior base modifications. Similar variations in gel band intensity are readily apparent with the different DNAs. It can be seen that all the adenine residues without exception show a high and practically equal degree of enhanced reactivity. None of the guanine residues, poorly represented in the control lane, appear to be hyperreactive in the presence of the drug. Thus, with the exception of a single T at position 93, the reaction is selective for A residues. Correlations between these hyperreactive sites and the ellipticine binding sites on this DNA fragment may be observed. The DNAase I differential cleavage plot (Fig. 3) shows that the GC rich region at position 72 -89 corresponds to a preferred binding site flanked by two A-rich regions of enhanced cutting at positions 64-68 and 80-86. A densitometric trace of the DEPC reaction shown on Figure 6 reveals that in the binding site 72-81 none of the five purines (all G) are hyperreactive to DEPC while either at the 3'-or 5'-sides of the drug binding site, adenines are markedly enhanced by the chemical probe. All the guanine residues, even those contained in regions of enhanced cutting by DN Aase I (see for example position G94 and G86 on the Watson strand), are protected from the reaction with DEPC. This indicates that GpX dinucleotides provide a site for ellipticine binding. It is worth noting that the pattern of DEPC reactivity remains effectively constant in the drug concentration range 2.5/xM to 50 jtM, consistent with the DNAase I footprinting study where the druginduced cutting pattern remained essentially constant over the range 1-20/tM. The patterns of hyperreactivity are presented as histograms for the 117bp and the 253bp pBS fragments (Figure 7) . Inspection of the DEPC hyperreactivity patterns with these fragments tends to confirm the previous observations with the tyr T DNA. The lanes from drug-treated samples are markedly different from the control. Adenine residues display a more or less equally enhanced reactivity towards DEPC in the presence of the drug whereas guanine residues are weakly affected or not at all. For example, the GGG site at position 44-46 on the 253bp DNA fragment is practically unaffected by DEPC treatment while the surrounding A-rich sites at position 37-43 (AAAACAA) and 47-50 (AAAT) are markedly affected. Once again, a good correlation exists between positive footprinting with DEPC and negative footprinting (i.e. the suppression of bands) with DNAase I; the GGG site (44-46) is a binding site and the A-rich sites 37 -43 and 47-50 are regions of enhanced cleavage by DNAase I (Figure 4) . Likewise, the weaker discrimination between enhancement at A and unreactivity at G by DEPC treatment with these pBS fragments compared to the tyr T fragment is in agreement with the weaker values of differential cleavage measured by DNAase I footprinting with these DNAs. Thus the equivalence of effect of the drug upon binding to three different DNA fragments of heterogeneous sequence is consistent with its deduced binding preference.
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Methylation by dimethylsulphate
G-specific sequencing of the DNAs in the presence or absence of ellipticine has been carried out using dimethylsulphate (DMS)-piperidine treatment. As the ellipticine exhibits a preferential binding to GC-rich sequences, the methylation of G by DMS might be affected by the presence of the bound drug. With the tyr T DNA, to which the drug binds with some evident sequenceselectivity, no changes were observed in the sensitivity to DMS. Upon DMS treatment of the 253bp DNA fragment of pBS, even at high ellipticine concentrations, every G band persists, regardless of its position within the sequence, suggesting that the accessibility of the N 7 position of the guanine residues is unaffected by drug binding. However inspection of the corresponding densitometric tracing (data not shown) revealed the appearance of a strong new band in the pattern at position 159, i.e. at an adenine residue.
Photocleavage
Ellipticine has an extended T-electron system and may act as a photosensitizer. The 117 base pair pBS fragment was used to study ellipticine-photosensitised DNA cleavage at the nucleotide level. To determine the optimal conditions for ellipticine induced photocleavage, the DNA fragment was incubated with concentrations of drug in the range 1-50 /iM. Without alkaline treatment, photolysis in the presence of the ellipticine derivative leads to a discrete set of products, identified mainly as representing cleavage at guanine sites. The cleaved fragments co-migrate with those obtained during the Maxam-Gilbert procedure. Therefore, they carry a terminal 3'-phosphate group. The observed cleavage is strongly enhanced after treatment with IM piperidine at 90°C for 15 minutes. This reaction reveals that modification of guanines predominates over cleavage of the phosphodiester bonds, following irradiation in the presence of the drug. These alkali-labile sites most probably result from photooxidation of guanines. It can be estimated that the treatment with hot piperidine causes an approximately 5-fold increase in the number of nicks produced by photoreaction of the drug with DNA.
The microdensitometric scanning data presented in Figure 8 show that the reactivity of guanines, which appear to be by far the most reactive base, is weakly dependent on neighbouring bases. Although the G-specific DNA cleavage occurred unequally at different G sites (for example compare the relative intensity of the G36 and G37 with the relative intensity of the same G bands in the G track), no great difference can be noted. Close inspection revealed that the ellipticine degradation of DNA produces single discrete bands and it is clear that every G residue appears as a photocleavage point whatever its location within the DNA sequence. G residues situated in a binding site (such as the G at position 58) or in a site of DNAase I enhanced cleavage (such as the G at positions 67-69) are almost identically cleaved. Furthermore the relative intensity of the G peaks, revealed by photoexcitation plus piperidine treatment, is more or less comparable to that revealed by the DMS-piperidine treatment [25] . Low concentrations of ellipticine (0.5-5/iM) result in considerable piperidine-revealed DNA breakage. At higher concentrations (50/iM) the strand scission pattern becomes less specific while at very high ellipticine concentration (150/iM), cleavage occurs identically at all nucleotides (data not shown).
DISCUSSION
The results presented here indicate that a functionalized ellipticine derivative changes the DNA cleavage pattern produced by a variety of footprinting agents. Motifs common to several footprinting agents are seen in the presence of drug using different DNA substrates. We infer that these changes in cleavage pattern reflect sequence selectivity in the binding of the drug to DNA. The activity of DNAase I is inhibited by the presence of the drug and more enzyme is needed to maintain an optimal degree of cleavage when drug is present. Consequently, relative rather than absolute changes in DNAase I cleavage rates are estimated. Thus it can be argued that the enhanced cleavage seen at runs of A or T in the presence of drug is a consequence of increased DNAase I concentrations rather than of drug binding. However, we think it unlikely for several reasons. Firstly, adjusting the enzyme concentration in the presence of drug influences the total degree of cleavage without producing marked changes in relative band intensities. Secondly the presence of drug induces similar changes in hydroxyl radical and DNAase I footprinting. Finally, the drug-sensitised photolysis of DNA and drug-induced changes in the DEPC cleavage patterns are complementary to those found with DNAase I. Thus we would argue that runs of A or T residues are rendered more susceptible to cleavage by the binding of drug to DNA.
The enhanced cleavage at AT regions may be due to redistribution of DNAase I over the nucleic acid fragment [28] . However, the lack of a correlation between DNAase I concentration and specific enhancement of cleavage at A or T rich sequences suggests that the enhanced cleavage rates at such sequences are not strongly DNAase limited. Enhancement effects occurring at AT-rich regions have previously been explained in terms of neighbouring ligand-induced local widening of the minor groove, converting it to a more average 'B-DNA like' structure [18, 21] . The propensity of this drug to induce similar enhancement may be correlated with its high unwinding angle (close to the 26° observed for ethidium bromide). Alternating AT tracts in DNA are thought to possess an unusual structure which is relatively easy to deform [29, 30] ; it is thus not surprising that ligand binding to adjacent regions can exert significant effects. Indeed, DNA structural changes upon binding of the ellipticine derivative are evidenced by the hyperreactivity of the drug-bound DNA toward DEPC (see below).
The conformational changes upon binding might be expected to improve the rate of cutting by DNAase I at runs of A and T nucleotides when GC sites are protected. A and T are associated with a relatively narrow minor groove on account of the high propeller twist of the steps ApA, ApT and TpA [31, 32] . If the bound drug induces local widening of the minor groove, DNAase I cutting at these sites ought to be facilitated. A possible explanation for the requirement of higher enzyme concentration to cleave the DNA in reasonable yield might be that the drug stabilizes the enzyme-DNA complex, inhibiting thus the DNAase I cutting reaction. Such trapping of an enzyme-DNA complex by ellipticine has been reported with topoisomerase II. Selective entrapment of nuclear protein by other intercalating drugs (such as doxorubicin) has also been observed [33] .
The footprinting data suggest that binding of this ellipticine derivative to DNA results in enhanced cleavage at sequences excluded from binding. However, protection from enzymic or hydroxyl radical induced cutting at binding sites is often less marked. The drug may apparently bind to many types of sequences. The present situation is more or less similar to that reported with ethidium [34] since both intercalators discriminate against runs of A and T. But as the two drugs have been tested on the same DNA fragment (the tyr T DNA fragment), more precise comparisons can be drawn. The intensity of blockage is generally more pronounced with the ellipticine, especially in the GC rich region from nucleotide positions 69 to 78, a sequence where no protection was apparent with ethidium. Thus the ellipticine derivative does produce a selective effect upon GC rich sequences. However, preferential binding to GC-rich sites is not a universal consequence of. intercalation since amsacrine produced no detectable changes in the relative DNAase I cutting pattern even at a concentration as high as lmM (unpublished data) and moreover AT-specific intercalators have been designed [35] .
Binding of the ellipticine derivative to DNA causes a marked increase in reactivity towards diethylpyrocarbonate. DEPC normally reacts with both guanosine and adenosine to cause opening of the imidazole ring and carboxyethylation at N 7 . Adenosine, which is more reactive than guanosine, is carboxyethylated at the exocyclic N 6 amino group as well [27] . In the presence of ellipticine, the increased carboxyethylation is confined to adenosine residues.
Upon binding to DNA, a large unwinding effect has been detected which could account for some of the increased reactivity. However other GC-specific monofunctional intercalators which also cause similar unwinding do not affect (e.g. actinomycin [22] ) or require high concentration (e.g. ethidium bromide [29] ) to affect the DEPC-mediated cleavage pattern. Moreover, quinoxaline antibiotics like echinomycin and triostin A which also display a strong GC selective binding, cause enhanced reactivity towards DEPC, mainly at adenosine residues but certain guanosines are also rendered susceptible [23] . In fact the DEPC pattern produced by this ellipticine derivative is comparable to that seen with the synthetic quinoxaline drug TANDEM (des-N-tetramethyltriostin A) which interacts preferentially with ATrich sites of DNA [36] and recognizes the sequence TpA [37] ): here again hyperreactivity to DEPC is confined to A residues. Thus this A-specific hyperreactivity can be attributed neither to unwinding alone nor to a characteristic feature of GC-preferred intercalation.
We note also that it is practically sequence neutral: each A is almost equally affected regardless of its position within the sequence and of its proximity to a GC binding site. Evidently each ligand has a peculiar effect on DNA structure which it is not yet possible to explain at the molecular level. Meanwhile, as it is essentially DEPC reaction at N 7 of purines which leads to scission of the DNA chain [38] , it would appear that the N 7 residue of adenines is still accessible whereas the N 7 of guanines is not though the exocyclic amino group might also provide an alternative reactive site for adenine [39] .
Experiments carried out with DMS reveal that the presence of the drug clearly has no effect on the methylation reaction. Thus intercalation of the ellipticine renders the guanine N 7 position still liable to attack by DMS. The appearance of a strong new band in the DMS pattern at position 159 probably results from modification at position N 3 of the adenine since it is known that modification at this position can generate an alkali-labile site. But the molecular significance of this new reactive site remains puzzling.
In a further attempt to define the reactivity of this ellipticine towards G sites, experiments have been performed in the presence of methylene blue. Exposure of DNA to methylene blue and visible light has been shown to cause guanine-specific modifications, and subsequent treatment with piperidine leads to chain cleavage at the modified guanine residues [26] . But this ellipticine derivative does not affect the reaction with methylene blue (data not shown). Such a lack of effect has been reported with daunomycin and ethidium bromide, whereas other intercalators like actinomycin D and nogalamycin strongly affect the methylene blue photosensitized guanine-specific reaction [40] .
The observation that the N 7 of guanine is not accessible to carboxyethylation but can be easily methylated is quite interesting. Inhibition of the reaction of DMS with N 7 of guanines has been reported with nogalamycin, which has bulky sugar substituents that come to lie in both major and minor DNA grooves [41] . Actinomycin D, which intercalates via the minor groove has little or no effect on the DMS reaction. Thus the continued DMS reactivity at guanines might suggest that the ellipticine derivative intercalates between base pairs via the minor groove.
On the other hand, a crystallographic study on the iodoCpGellipticine complex [42] has shown that the quaternizable nitrogen of the pyridine ring is pointing towards the major groove. If a similar orientation of the chromophore were to apply to the present ellipticine derivative, the side chain at position 1 might be located in the major groove. In addition, the unmodified reactivity of the DNA-ellipticine complex towards methylene blue also suggests major groove binding of the side chain since methylene blue photocleavage is highly sensitive to protection in the minor groove. These considerations suggest that the aminoalkylamino side chain linked to this ellipticine derivative might well lie in the major groove without affecting the DMS reaction, for in steric bulk it is in no way comparable to the sugar side chains of nogalamycin or the peptide rings of actinomycin. But we are at a loss to explain why DEPC reactivity should be confined to adenosine residues in the presence of the drug.
The pronounced preference for modification at guanosines following photoexcitation of the ellipticine-DNA complex may be directly related to the protection of guanines from reaction with DEPC. Taken together, these results indicate that this ligand may even be used as part of a photochemical DNA sequencing strategy or as a base-directed DNA modifying reagent.
The techniques used here vary in informativeness. At one extreme, DNAase I footprinting defines the degree of selectivity in binding. At the other, the negative results with methylene blue may indicate preferential major groove binding; but this is unsubstantiated. All the footprinting techniques suggest that a variety of preferred binding sequences exist but that A or T rich sequences are not favoured. The observations of photocleavage corroborate the findings of the footprinting studies. Finally, knowledge of the capacity for sequence-specific recognition of DNA by this ellipticine derivative can have interesting implications. It helps (i) in understanding the topoisomerase IImediated site-specific DNA cleavage in the presence of ellipticine, (ii) in aiding the design of drugs having substituents coupled to the activated amino group of this compound.
